← FDA Drug Approvals (Drugs@FDA)

DIFLUPREDNATE

ANDA · Abbreviated New Drug Application (Generic) · Sponsor: CIPLA · Approved 2021-08-09

Drug application

FDA Application #
ANDA211776
Application type
Abbreviated New Drug Application (Generic)
Brand name
DIFLUPREDNATE
Generic name
DIFLUPREDNATE
Active ingredients
DIFLUPREDNATE
Dosage form
EMULSION
Route
OPHTHALMIC
Marketing status
Prescription
Sponsor
CIPLA
Manufacturer
Cipla USA Inc.
First approval
2021-08-09

Source

Authoritative
Drugs@FDA application overview
Machine
JSON-LD · Markdown